title: [IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma].
abstract: BRIIL-2 is a clinical study for evaluation of efficacy and toxicity of third line treatment of pulmonary metastasis from renal cancer and melanoma with flexible bronchoscopic istillation of IL-2. Moreover, we evaluate local (BALT) and peripheral lymphocytic activation during this IL-2 administration. Up today we enrolled two patients with pulmonary metastasis from renal cancer already treated with two lines of molecular therapy, chemotherapy or systemic immunotherapy. Regarding to immunologic stimulation, lymphocytic fraction decreased from 21 to 2% in the first and from 10.5 to 6% in the second patient, indicating lymphocytic enrollment for activation, while TCD4/CD8 ratio is stable. In both patients we also observed a significant increase of HLA-DR in T lymphocytes (CD3) either in BAL or in peripheral blood. No significant major toxicities were observed after broncho-istillation, even if the dose was progressively increased. Thus IL-2 broncho-istillation could represent a valid administration modality to obtain an effective immunologic stimulation either local or systemic.
authors.affiliation: Endoscopia Toracica, Istituto Regina Elena, Via Elio Chianesi 53, Rome, Italy. mfilippetti@ifo.it
authors.forename: M
authors.initials: M
authors.lastname: Filippetti
authors.forename: A
authors.initials: A
authors.lastname: Torsello
authors.forename: P
authors.initials: P
authors.lastname: Cordiali Fei
authors.forename: V
authors.initials: V
authors.lastname: Bordignon
authors.forename: E
authors.initials: E
authors.lastname: Trento
authors.forename: R
authors.initials: R
authors.lastname: Tonachella
authors.forename: G
authors.initials: G
authors.lastname: Piperno
authors.forename: G
authors.initials: G
authors.lastname: Prignano
mesh_terms: D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D001999:Bronchoscopy; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000276:immunology / Q000556:secondary* / Q000601:surgery / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005336:Fiber Optic Technology; D006684:HLA-DR Antigens / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007322:Instillation, Drug; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology / Q000556:secondary* / Q000628:therapy; D008213:Lymphocyte Activation / Q000187:drug effects; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D009392:Nephrectomy; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism
chemical_list: D006684:HLA-DR Antigens; D007376:Interleukin-2